Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs

References

• GrecoFVicentMJCombination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicinesAdv Drug Deliv Rev200961131203121319699247
   PubMed Web of Science ®Google Scholar
• BroxtermanHJGeorgopapadakouNHAnticancer therapeutics: “Addictive” targets, multi-targeted drugs, new drug combinationsDrug Resist Updat20058418319716154800
   PubMed Web of Science ®Google Scholar
• GeeJHowellAGullickWConsensus statementEndocr Relat Cancer200512Suppl 1S1S716113086
   PubMedGoogle Scholar
• HoneckerFKollmannsbergerCQuietzschDPhase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancerAnticancer Drugs200213549750312045461
   PubMed Web of Science ®Google Scholar
• PriottoGKasparianSMutomboWNifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trialLancet20093749683566419559476
   PubMed Web of Science ®Google Scholar
• SuriSSFenniriHSinghBNanotechnology-based drug delivery systemsJ Occup Med Toxicol2007211618053152
   PubMedGoogle Scholar
• FarokhzadOCLangerRImpact of nanotechnology on drug deliveryACS Nano200931162019206243
   PubMed Web of Science ®Google Scholar
• WagnerVDullaartABockA-KZweckAThe emerging nanomedicine landscapeNat Biotechnol200624101211121817033654
   PubMed Web of Science ®Google Scholar
• YuanFDellianMFukumuraDVascular permeability in a human tumor xenograft: molecular size dependence and cutoff sizeCancer Res19955517375237567641188
   PubMed Web of Science ®Google Scholar
• LaginhaKMumbengegwiDAllenTLiposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicityBiochim Biophys Acta200517111253215904660
   PubMed Web of Science ®Google Scholar
• StormGBelliotSODaemenTLasicDDSurface modification of nanoparticles to oppose uptake by the mononuclear phagocyte systemAdv Drug Deliv Rev19951713148
   Web of Science ®Google Scholar
• NieSUnderstanding and overcoming major barriers in cancer nanomedicineNanomedicine20105452352820528447
   PubMed Web of Science ®Google Scholar
• MoghimiSMGrayTA single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in ratsClin Sci19979343713799404230
   PubMed Web of Science ®Google Scholar
• DamsETLavermanPOyenWJAccelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomesJ Pharmacol Exp Ther200029231071107910688625
   PubMed Web of Science ®Google Scholar
• WangCChengXSuiYA noticeable phenomenon: thiol terminal PEG enhances the immunogenicity of PEGylated emulsions injected intravenously or subcutaneously into ratsEur J Pharm Biopharm201385374475124129310
   PubMed Web of Science ®Google Scholar
• KoideHAsaiTHatanakaKParticle size-dependent triggering of accelerated blood clearance phenomenonInt J Pharm20083621–219720018586076
   PubMed Web of Science ®Google Scholar
• ZhaoYXWangLYanMNRepeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beaglesInt J Nanomedicine201272891290022745552
   PubMed Web of Science ®Google Scholar
• KaminskasLMMcleodVMPorterHChristopherJBoydBJDifferences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearanceJ Pharm Sci2011100115069507721721002
   PubMed Web of Science ®Google Scholar
• Abu LilaASKiwadaHIshidaTThe accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manageJ Control Release20131721384723933235
   PubMed Web of Science ®Google Scholar
• PozziDColapicchioniVCaraccioloGEffect of polyethyleneglycol (PEG) chain length on the bio–nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cellsNanoscale2014652782279224463404
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human ServicesPublic Health ServiceNational Institutes of HealthGuide for the Care and Use of Laboratory AnimalsWashington, DCNational Academy Press1985
   Google Scholar
• ZhaoYXWangCLWangLA frustrating problem: accelerated blood clearance of PEGylated solid lipid nanoparticles following subcutaneous injection in ratsEur J Pharm Biopharm201281350651322580209
   PubMed Web of Science ®Google Scholar
• SongHGengHRuanJDevelopment of Polysorbate 80/Phospholipid mixed micellar formation for docetaxel and assessment of its in vivo distribution in animal modelsNanoscale Res Lett201161112
   Google Scholar
• ShimadaKMiyagishimaASadzukaYDetermination of the thickness of the fixed aqueous layer around polyethyleneglycol-coated liposomesJ Drug Target1995342832898821002
   PubMed Web of Science ®Google Scholar
• SadzukaYNakadeATsurudaTSonobeTStudy on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicinJ Control Release200391327128012932707
   PubMed Web of Science ®Google Scholar
• SadzukaYNakadeAHiramaREffects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposomeInt J Pharm2002238117118011996821
   PubMedGoogle Scholar
• WilsonDRZhangNSilversALForstnerMBBaderRASynthesis and evaluation of cyclosporine A-loaded polysialic acid–polycaprolactone micelles for rheumatoid arthritisEur J Pharm Sci20145114615624075961
   PubMed Web of Science ®Google Scholar
• IchiharaMShimizuTImotoAAnti-PEG IgM response against PEGylated liposomes in mice and ratsPharmaceutics20103111124310423
   PubMedGoogle Scholar
• IshidaTIchikawaTIchiharaMSadzukaYKiwadaHEffect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in miceJ Control Release200495340341215023452
   PubMed Web of Science ®Google Scholar
• WangXYIshidaTIchiharaMKiwadaHInfluence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in ratsJ Control Release200510419110215866337
   PubMed Web of Science ®Google Scholar
• IshiharaTTakedaMSakamotoHAccelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticlesPharm Res200926102270227919633820
   PubMed Web of Science ®Google Scholar
• WangXIshidaTKiwadaHAnti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomesJ Control Release2007119223624417399838
   PubMed Web of Science ®Google Scholar
• JanewayCATraversPWalportMShlomchikMJImmunobiologyNew York, NYGarland Science2001910
   Google Scholar
• SzebeniJMuggiaFGabizonABarenholzYActivation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and preventionAdv Drug Deliv Rev201163121020103021787819
   PubMed Web of Science ®Google Scholar
• OwensDEIIIPeppasNAOpsonization, biodistribution, and pharmacokinetics of polymeric nanoparticlesInt J Pharm200630719310216303268
   PubMed Web of Science ®Google Scholar
• LavermanPCarstensMGBoermanOCFactors affecting the accelerated blood clearance of polyethylene glycolliposomes upon repeated injectionJ Pharmacol Exp Ther2001298260761211454922
   PubMed Web of Science ®Google Scholar
• JiskootWvan SchieRMCarstensMGSchellekensHImmunological risk of injectable drug delivery systemsPharm Res20092661303131419247815
   PubMed Web of Science ®Google Scholar
• MüllerRRadtkeMWissingSSolid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparationsAdv Drug Deliv Rev200254S131S15512460720
   PubMed Web of Science ®Google Scholar
• IshidaTWangXShimizuTNawataKKiwadaHPEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent mannerJ Control Release2007122334935517610982
   PubMed Web of Science ®Google Scholar
• MondJJLeesASnapperCMT cell-independent antigens type 2Annu Rev Immunol19951316556927612238
   PubMedGoogle Scholar
• MondJJVosQLeesASnapperCMT cell independent antigensCurr Opin Immunol1995733493547546399
   PubMed Web of Science ®Google Scholar
• JoshiMDMüllerRHLipid nanoparticles for parenteral delivery of activesEur J Pharm Biopharm200971216117218824097
   PubMed Web of Science ®Google Scholar
• LiuKSunJHeZ-gDevelopment on novel nanostructured lipid carriersJ Shenyang Pharm Univ20083017
   Google Scholar
• ChengT-LChenB-MChernJ-WWuM-FRofflerSREfficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapyBioconjug Chem200011225826610725103
   PubMed Web of Science ®Google Scholar
• ChengT-LWuP-YWuM-FChernJ-WRofflerSRAccelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgMBioconjug Chem199910352052810346886
   PubMed Web of Science ®Google Scholar
• LiS-DHuangLStealth nanoparticles: high density but sheddable PEG is a key for tumor targetingJ Control Release2010145317820338200
   PubMed Web of Science ®Google Scholar
• NeedhamDStoichevaNZhelevDVExchange of monooleoylphosphatidylcholine as monomer and micelle with membranes containing poly(ethylene glycol)-lipidBiophys J1997735261526299370456
   PubMed Web of Science ®Google Scholar
• GarbuzenkoOBarenholzYPrievAEffect of grafted PEG on liposome size and on compressibility and packing of lipid bilayerChem Phys Lipids2005135211712915921973
   PubMed Web of Science ®Google Scholar
• TorchilinVPOmelyanenkoVGPapisovMIPoly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevityBiochim Biophys Acta19941195111207918551
   PubMed Web of Science ®Google Scholar
• BastenASilveiraPAB-cell tolerance: mechanisms and implicationsCurr Opin Immunol201022556657420829011
   PubMed Web of Science ®Google Scholar
• HashimotoYShimizuTMimaYAbu LilaASIshidaTKiwadaHGeneration, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMsToxicol Appl Pharmacol20142771303824632081
   PubMed Web of Science ®Google Scholar